Policy & Regulation
Angel Pharmaceuticals' mupadolimab IND application receives Chinese regulatory approval
27 September 2022 -

Angel Pharmaceuticals Ltd., a China-based clinical-stage biopharmaceutical company, announced on Monday that it has received approval from China's Center for Drug Evaluation (CDE) for the IND application relating to mupadolimab (formerly CPI-006) to start a phase 1/1b clinical trial in China.

Angel Pharma owns mupadolimab's rights in Greater China.

Mupadolimab is a humanised monoclonal antibody directed against CD73. In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. Compared with other anti-CD73 antibodies and small molecule drugs in development, mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine with a proposed unique mechanism of activating B cells to generate immune responses to tumour antigens and viruses.



Related Headlines